Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.

ABSTRACT:

Background

Cediranib (AZD2171) is a potent small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors. Cediranib has demonstrated single agent activity in several adult cancers and is being studied in combination with standard cytotoxic agents in multiple disease settings.

Procedures

Cediranib was tested in vivo against six childhood tumor xenograft models (four sarcomas, one glioblastoma, one neuroblastoma) alone or combined with cyclophosphamide (two models), vincristine (three models) or cisplatin (one model), each administered at its maximum tolerated dose, or rapamycin (six models).

Results

The combination of cediranib with standard cytotoxic agents was superior to the cytotoxic agent used alone for a single xenograft (one of the three xenogr

SUBMITTER: Morton CL 

PROVIDER: S-EPMC3253323 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature